Finch Therapeutics Group, Inc.

Finch Therapeutics Group, Inc. is a clinical-stage microbiome therapeutics company focused on developing orally administered biological drugs. Its lead candidate, CP101, is in Phase 3 clinical trial for recurrent Clostridioides difficile infection and chronic hepatitis B virus. The company also develops FIN-211 for autism spectrum disorder, and TAK-524 and FIN-525 for ulcerative colitis and Crohn's disease. Finch generates revenue through the development and commercialization of these microbiome-based therapeutics, leveraging collaboration and license agreements with partners such as Takeda Pharmaceutical Company Limited, Skysong Innovations LLC, and University of Minnesota.

Products

• CP101 for recurrent Clostridioides difficile infection and chronic hepatitis B virus

• FIN-211 for autism spectrum disorder

• TAK-524 and FIN-525 for ulcerative colitis and Crohn's disease